Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin‐Biroulet, Toshimitsu Fujii, Matthew Germinaro et al.|Gastroenterology|2023Cited by 97
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialMillie Long, James Fon, Jessica R. Allegretti et al.|The Lancet. Gastroenterology & hepatology|2026Cited by 6